A compound represented by formula (I'): (wherein m, n, and p each represent 0 to 2； q represents 0 or 1； R 1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO 2 group, or the like； R 2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group； X 1 represents O, -NR 3 -, or -S(O)r-； X 2 represents a methylene group, O, -NR 3 -, or - S(O)r-； Q' represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group； Cycle moiety represents an aryl ring or a heteroaryl ring； and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.
